Are circulating tumor cells an independent prognostic factor in patients with high-risk melanoma?

Nature Clinical Practice Oncology

Volumn 1, Issue 2, 2004, Pages 74-75

  Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Adjuvant therapy; Circulating tumor cell; Cutaneous melanoma; Disease recurrence; Prognosis

Indexed keywords

ALPHA INTERFERON;

CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG MEGADOSE; HIGH RISK POPULATION; HUMAN; LYMPH NODE METASTASIS; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SHORT SURVEY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR CELL; TUMOR VOLUME;

CHEMOTHERAPY, ADJUVANT; HUMANS; MELANOMA; NEOPLASM CIRCULATING CELLS; PROGNOSIS; RISK FACTORS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 20444505574     PISSN: 17434254     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncponc0041     Document Type: Short Survey

References (5)

1. Smith B et al. (1991) Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338: 1227-1229
2. Hoon DS et al. (2000) Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 60: 2253-2257
3. Wascher RA et al. (2003) Molecular tumor markers in the blood: Early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J Clin Oncol 21: 2558-2563
4. Keilholz U et al. (2004) Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin Cancer Res 10: 1605-1612
5. Taback B et al. (2004) Circulating DNA microsatellites: Molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J Natl Cancer Inst 96: 152-156